Kathryn Gray, PA
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations.
Across 64 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$140
- Astellas Pharma US Inc$137
- Amgen$136
- Novo Nordisk$58
- GSK$51
- Merck$35
- plus $564 from 30 others
What the payments were for
- Food & beverage$1,122100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 6 | $140 |
| Astellas Pharma US Inc | 7 | $137 |
| Amgen | 8 | $136 |
| Novo Nordisk | 3 | $58 |
| GSK | 3 | $51 |
| Merck | 2 | $35 |
| AstraZeneca(2 entities) | 2 | $33 |
| Baxter Healthcare | 2 | $32 |
| Lilly USA, LLC | 2 | $31 |
| Lundbeck LLC | 2 | $29 |
| Exact Sciences | 2 | $28 |
| Philips North America LLC | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Boston Scientific | 1 | $21 |
| Madrigal Pharmaceuticals | 1 | $21 |
| Boehringer Ingelheim | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Viiv Healthcare Company | 1 | $18 |
| Organogenesis Inc. | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Novartis | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Organon | 1 | $16 |
| Pfizer | 1 | $15 |
| Abbott | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Intercept Pharmaceuticals, Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Mylan Specialty L.p. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
How this compares
$1,122 in reported general payments places this provider in the 80th percentile of 51 medical providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 27 | $27,625 |
| OzempicSemaglutide | 26 | $24,265 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $7,791 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $6,780 |
| Metoprolol Succinate | 69 | $1,309 |
| Levothyroxine Sodium | 111 | $1,152 |
| Atorvastatin Calcium | 117 | $1,063 |
| Losartan Potassium | 80 | $968 |
| Duloxetine Hcl | 24 | $812 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $804 |
| Bupropion XlBupropion Hcl | 28 | $780 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 33 | $729 |
| Lisinopril | 82 | $620 |
| Gabapentin | 34 | $613 |
| Amlodipine Besylate | 74 | $601 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $31 | $27,62527 claims |
| Novo NordiskOzempic | $58 | $24,26526 claims |
| GSKTrelegy Ellipta | $51 | $6,78011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 51 medical providers in North Dakota.
Other medical in Fargo
- Gregory BjorklundFargo$47K
- Angela WagnerFargo$4K
- Debra AndvikFargo$3K
- David TullarFargo$2K
- Catherine GarveyFargo$2K
- Melissa ChristensenFargo$2K
- Dacia EngbergFargo$1K
- Jamie BrownFargo$968
- Susan HansonFargo$709
- Yan TeschFargo$509
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.